Organon & Co. (OGN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, OGN scores 70 out of 100, a letter grade of B-, with the verdict label "Roarable Buy — Sound Institutional Accumulation." The fundamental cash engine pillar scores 18 of 20, supported by ROIC of 24.9% and an FCF yield of 14.83%, which is the strongest component of the rating and suggests the business generates substantial returns relative to capital employed. The whale 13F flow pillar scores 16 of 20 and the insider conviction pillar scores 16 of 20, both reflecting institutional accumulation and SEC Form 4 and Congressional PTR cluster flow as described in the rating. The forensic balance sheet pillar scores 11 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 6 out of 9, and a Debt/Equity of 8.5. The macro regime fit pillar is the weakest at 9 of 20, reflecting a beta of 1.0 and sector sensitivity. For a prospective investor, the upside case rests on cash generation and capital returns, while the valuation and balance sheet tradeoffs are the principal considerations. The rating is a model output and does not constitute personalized financial advice.

Organon & Co. (OGN) is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the profile section. Source data does not describe its specific products, customers, or revenue model. Per the SEC financials, the company reported revenue of $6216.0M for FY 2025. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE."

Per the SEC financials, revenue declined from $6403.0M in FY 2024 to $6216.0M in FY 2025, and net income declined from $864.0M to $187.0M over the same period. Per the market data, gross margin is 53.3%, operating margin is 0%, and net margin is 3%. The RQD rating cites ROIC of 24.9%, an Altman Z of 2.5, and a Piotroski F of 6 out of 9. Debt was $8628.0M against cash of $574.0M at FY 2025, and the rating cites a Debt/Equity of 8.5.

Per the recent news section, five wire items reference OGN and are all tagged as market wire with a yellow signal. Headlines include a 52-week high report at 13.79 USD from Investing.com and a Stock Titan item stating that Q3 revenue fell to $1.57B while profit moved the other way. The remaining items are general quote and trending-stock pages without specific catalyst content. Per the Butterfly Supply-Chain Graph, there are no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply_chain is "NONE" and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is the Health Care classification.

• What drives the decline in net income from $1023.0M in FY 2023 to $187.0M in FY 2025, and is it recurring or one-time?
• Why is operating income reported as $0.0M across all periods, and how should the 0% operating margin be interpreted?
• What is the company's debt maturity profile and interest burden relative to its $8628.0M debt load?
• What products and customers generate the revenue, and what is the supply-chain dependency structure?
• What are the analyst consensus, price targets, and 13F or insider holdings beyond the rating's qualitative description?